

**Baxter International Inc.**  
**Key Product Line Sales -- US/International**  
**Period Ending December 31, 2004**  
(unaudited)

(\$ in millions)	Q4 2004			Q4 2003			% Growth		
	US	International	Total	US	International	Total	US	International	Total
<b>BioScience</b>									
Recombinants	\$173	\$203	\$376	\$172	\$163	\$335	1%	25%	12%
Plasma Proteins <sup>1</sup>	118	160	278	151	144	295	(22%)	12%	(6%)
Antibody Therapy	46	38	84	58	38	96	(20%)	0%	(12%)
Transfusion Therapies	76	74	150	76	74	150	0%	0%	0%
Other <sup>2</sup>	35	29	64	17	43	60	111%	(36%)	5%
<b>Total BioScience</b>	<b>\$448</b>	<b>\$504</b>	<b>\$952</b>	<b>\$474</b>	<b>\$462</b>	<b>\$936</b>	<b>(5%)</b>	<b>9%</b>	<b>2%</b>
<b>Medication Delivery</b>									
IV Therapies <sup>3</sup>	\$104	\$205	\$309	\$116	\$190	\$306	(11%)	8%	1%
Drug Delivery	186	55	241	147	48	195	26%	16%	24%
Infusion Systems	182	54	236	204	49	253	(10%)	9%	(7%)
Anesthesia	214	20	234	208	21	229	3%	(5%)	2%
Other <sup>4</sup>	8	101	109	10	104	114	(19%)	(3%)	(4%)
<b>Total Medication Delivery <sup>5</sup></b>	<b>\$694</b>	<b>\$435</b>	<b>\$1,129</b>	<b>\$685</b>	<b>\$412</b>	<b>\$1,097</b>	<b>1%</b>	<b>6%</b>	<b>3%</b>
<b>Renal</b>									
PD Therapy	\$65	\$317	\$382	\$65	\$302	\$367	0%	5%	4%
HD Therapy	35	99	134	32	94	126	8%	5%	6%
Other	3	1	4	3	2	5	14%	(52%)	(13%)
<b>Total Renal</b>	<b>\$103</b>	<b>\$417</b>	<b>\$520</b>	<b>\$100</b>	<b>\$398</b>	<b>\$498</b>	<b>3%</b>	<b>5%</b>	<b>4%</b>
<b>TOTAL BAXTER</b>	<b>\$1,245</b>	<b>\$1,356</b>	<b>\$2,601</b>	<b>\$1,259</b>	<b>\$1,272</b>	<b>\$2,531</b>	<b>(1%)</b>	<b>7%</b>	<b>3%</b>

<sup>1</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

<sup>2</sup> Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

<sup>3</sup> Principally includes intravenous solutions and nutritional products.

<sup>4</sup> Principally includes oncology and other hospital-distributed products.

<sup>5</sup> Sales of pain management products, which were previously included in Anesthesia, are now reported in Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.